Abstract:Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease. Its pathological features are dopaminergic neuronal death in the substantia nigra (SN), and significant reduction of dopamine (DA) content in the striatum. A large number of studies have found an increase in iron levels in PD patients and animal models, which suggested that brain iron metabolism dysfunction played a key role in the pathogenesis of PD. Lactoferrin (Lf) is a non‐heme iron‐binding glycoprotein belonging to the transferrin family, entering the cell membrane via a lactoferrin receptor (LfR)‐mediated pathway. Lf exists mainly in two forms: iron‐free‐lactoferrin (apo‐Lf) and iron‐saturated‐lactoferrin (holo‐Lf). Our previous studies found thatapo‐Lf and holo‐Lf exert neuroprotective effects against 1‐methyl‐4‐phenylpyridinium toxicity in ventral mesencephalon neurons in vitro. This study aimed to further investigate whether two different forms of Lf have neuroprotective effects in vivo, and to examine their mechanisms, so as to provide an experimental basis for finding new therapeutic strategies against PD. In the central nervous system, Lf antagonized 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced DA depletion in the striatum, iron deposition, oxidative and apoptotic processes in the SN. Lf treatment down‐regulated iron import protein divalent metal transporter1 (DMT1) and up‐regulated iron export protein ferroportin1 (Fpn1), attenuating MPTP induced accumulation of nigral iron level. In the peripheral system, Lf alleviated MPTP‐induced increases in serum iron and ferritin, and decreases in serum total iron binding capacity (TIBC), loss of spleen weight, and reduction of spleen iron content. The results indicate that Lf has a neuroprotective effect on MPTP‐induced PD model mice, and its mechanism may be related to anti‐iron dysregulation, anti‐oxidative stress, and anti‐apoptosis, with apo‐Lf showing greater efficacy. Therefore, Lf might be a promising therapeutic substance for PD.

Lactoferrin Protects Against Rotenone-Induced Toxicity in Dopaminergic SH-SY5Y Cells through the Modulation of Apoptotic-Associated Pathways

Identification of Novel Proteins Affected by Rotenone in Mitochondria of Dopaminergic Cells

Lactoferrin protects against iron dysregulation, oxidative stress, and apoptosis in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced Parkinson’s disease in mice

Lithium Protects Dopaminergic Cells from Rotenone Toxicity Via Autophagy Enhancement

Rotenone Impairs Autophagic Flux and Lysosomal Functions in Parkinson'S Disease

Resveratrol Partially Prevents Rotenone-Induced Neurotoxicity in Dopaminergic SH-SY5Y Cells through Induction of Heme Oxygenase-1 Dependent Autophagy

Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP-treated mice

Roflupram protects against rotenone-induced neurotoxicity and facilitates α-synuclein degradation in Parkinson’s disease models

7,8-Dihydroxyflavone Protects Nigrostriatal Dopaminergic Neurons from Rotenone-Induced Neurotoxicity in Rodents.

Lactoferrin: neuroprotection against Parkinson's disease and secondary molecule for potential treatment

Neuroprotective Effect of Acteoside Against Rotenone-Induced Damage of SH-SY5Y Cells and Its Possible Mechanism

Fucoidan Protects Dopaminergic Neurons by Enhancing the Mitochondrial Function in a Rotenone-induced Rat Model of Parkinson’s Disease

Astrocytic lactoferrin deficiency augments MPTP-induced dopaminergic neuron loss by disturbing glutamate/calcium and ER-mitochondria signaling

Growth Differentiation Factor 15 Protects SH-SY5Y Cells From Rotenone-Induced Toxicity by Suppressing Mitochondrial Apoptosis

Combined R-alpha-lipoic Acid and Acetyl-L-carnitine Exerts Efficient Preventative Effects in a Cellular Model of Parkinson's Disease.

Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model.

Minocycline Protects Against Rotenone-Induced Neurotoxicity Correlating with Upregulation of Nurr1 in a Parkinson's Disease Rat Model

Glyceraldehyde-3-phosphate Dehydrogenase: Activity Inhibition and Protein Overexpression in Rotenone Models for Parkinson's Disease

Astrocytic lactoferrin deficiency augments MPTP-induced dopaminergic neuron loss by disturbing ER-mitochondria signaling

Effect of Oleracein E, a Neuroprotective Tetrahydroisoquinoline, on Rotenone-Induced Parkinson's Disease Cell and Animal Models.

Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-Induced Ferroptosis in Dopaminergic Cells